No Data
No Data
Scynexis Initiates Dosing in Phase 1 Trial of SCY-247
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
Express News | Scynexis Initiates Dosing in Phase 1 Trial of Scy-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
US Manufacturing Index Rises To 43, Highest Since 2020
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and SCYNEXIS (SCYX)
SCYNEXIS's Strong Financial Position and Strategic Advancements Drive Buy Rating
loading...
芳晴 : Still falling all the way down.
Trytosaveabit OP 芳晴 : Sorry for late reply! Fridays I have to leave trading around 9:30AM! But yes it had just like no volume today! It will continue down or at least trade sideways until something happens to bring volume. Again apologies for late response. Hope you have a good weekend
芳晴 : Thank you for your reply, I'm not sure if it's still worth holding, it's too losses. Torture. Wishing you a Merry Christmas.
Trytosaveabit OP 芳晴 : You’re welcome! Merry Christmas!